Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Open Access

Immune monitoring in patients with colorectal cancer stage II

  • Eva Zavadova1,
  • Michal Vocka1,
  • Jan Spacek1,
  • Nicole Francis2,
  • Bohuslav Konopasek1,
  • Terezie Fucikova3,
  • Helena Skalova4,
  • Pavel Dundr4,
  • Lubos Petruzelka1,
  • Tilman T Rau5,
  • Carol Geppert5 and
  • Arndt Hartmann5
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P266


Published: 4 November 2015

Immunoscore has been shown to be a very powerful prognositc indicator in patients with clinically localized colorectal cancer, with no detectable tumour spread to lymph nodes or distant organs. These patients are usually treated with surgical removal of the tumour only. However, approximately 25% of these patients will have recurrence of their disease. No tumour-associated marker to predict the recurrence of this subgroup of patients and define who could benefit from adjuvant therapy is used in clinical routine[1] In addition to immunoscore, other parameters of the immune response are investigated – mostly cellular immunity and the production of immunosuppressive and neoangiogenic markers. Vascular endothelial growth factor (VEGF) is the factor responsible for neoangiogenesis and it is being considered as a possible prognostic marker of disease progression. Transforming growth factor-beta (TGF-beta) is also neoangiogenic and a highly immunosuppressive factor as it suppresses the body's natural immunity against tumours and is also being considered as another possible prognostic marker of disease progression.


To monitor the immune response in patients with stage II colorectal cancer, with a focus on cellular as well as humoral immunity. TGF-beta and VEGF levels were followed.


38 patients with stage II colon cancer included in the research project received routine cancer treatment. . Basic parameters – histological type and grade, proliferative markers – were established at baseline. Patients were evaluated by a clinical immunooncologist to exclude any immune disorders of allergic or autoimmune origin. TGF-beta and VEGF were measured using ELISA, and anti-tumour cellular immunity (CD4, CD8, T-reg, B cells) were measured via flow cytometry.


In patients with stage II colorectal cancer, predominantly a depression in cellular immunity was seen. Plasma levels of immunglobulins were also reduced, particularly the IgG3 subtype. Most patients showed some clinical symptoms of immunodeficiency, such as frequent respiratory tract infections and/or herpetic infections. TGF-beta and VEGF plasma levels were increased.


The correlation of these neoangiogenic and immunosuppressive factors, as well as the state of anticancer immunity, could help in the future as a prognostic marker and contribute to the selection of targeted adjuvant as well as immune therapy in patients with colorectal cancer stage II.


This project was supported by grant of Czech Ministery of Health, 15-28188A, League against cancer and PRVOUK.

Authors’ Affiliations

Department of Oncology, General Teaching Hospital and 1st Faculty of Medicine Charles University
1st Faculty of Medicine Charles University
Institute of immunology and microbiology, General Teaching Hospital and 1st Faculty of Medicine Charles University
Dept. of pathology, General Teaching Hospital and 1st Faculty of Medicine Charles University
Institute of Pathology, University Erlangen-Nürnberg


  1. Galon J, et al: Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. Journal of Pathology. 2014, 232 (2): 199-209.PubMedPubMed CentralView ArticleGoogle Scholar


© Zavadova et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.